ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 145 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2015. The put-call ratio across all filers is 0.83 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,033,544 | -77.4% | 916,011 | -72.8% | 0.00% | -100.0% |
Q1 2024 | $9,016,233 | +185.2% | 3,364,266 | +218.2% | 0.00% | +100.0% |
Q4 2023 | $3,161,629 | +174.1% | 1,057,401 | -10.2% | 0.00% | – |
Q3 2023 | $1,153,456 | +0.5% | 1,176,996 | +42.5% | 0.00% | – |
Q2 2023 | $1,147,738 | +3.0% | 825,711 | +17.8% | 0.00% | – |
Q1 2023 | $1,114,846 | -75.4% | 701,161 | -3.7% | 0.00% | -100.0% |
Q4 2022 | $4,537,545 | +145287.5% | 728,338 | +56.4% | 0.00% | 0.0% |
Q3 2022 | $3,121 | +87.6% | 465,799 | +78.1% | 0.00% | – |
Q2 2022 | $1,664 | -99.9% | 261,558 | -29.2% | 0.00% | – |
Q1 2022 | $1,715,000 | +19.3% | 369,511 | +28.6% | 0.00% | – |
Q4 2021 | $1,437,000 | +332.8% | 287,269 | +942.6% | 0.00% | – |
Q3 2021 | $332,000 | -59.2% | 27,553 | -28.4% | 0.00% | – |
Q2 2021 | $814,000 | +63.8% | 38,484 | +117.2% | 0.00% | – |
Q1 2021 | $497,000 | -80.5% | 17,718 | -82.0% | 0.00% | -100.0% |
Q4 2020 | $2,553,000 | +51.1% | 98,213 | +116.0% | 0.00% | – |
Q3 2020 | $1,690,000 | -89.4% | 45,469 | -85.4% | 0.00% | -100.0% |
Q2 2020 | $16,017,000 | +71.1% | 312,161 | +5.1% | 0.01% | +66.7% |
Q1 2020 | $9,361,000 | -61.3% | 296,886 | -26.8% | 0.00% | -50.0% |
Q4 2019 | $24,198,000 | +126.5% | 405,811 | +39.3% | 0.01% | +100.0% |
Q3 2019 | $10,683,000 | -47.5% | 291,419 | -33.4% | 0.00% | -50.0% |
Q2 2019 | $20,346,000 | +8.9% | 437,368 | -6.0% | 0.01% | 0.0% |
Q1 2019 | $18,675,000 | +21.4% | 465,133 | +39.1% | 0.01% | +20.0% |
Q4 2018 | $15,379,000 | +44.4% | 334,337 | +39.3% | 0.01% | +66.7% |
Q3 2018 | $10,650,000 | +23.5% | 240,018 | +9.1% | 0.00% | +50.0% |
Q2 2018 | $8,622,000 | -36.6% | 220,013 | +17.0% | 0.00% | -33.3% |
Q1 2018 | $13,597,000 | -39.2% | 187,998 | -44.6% | 0.00% | -40.0% |
Q4 2017 | $22,358,000 | +51.9% | 339,576 | +15.7% | 0.01% | +66.7% |
Q3 2017 | $14,715,000 | -0.7% | 293,596 | -8.3% | 0.00% | 0.0% |
Q2 2017 | $14,815,000 | +239.8% | 320,111 | +159.2% | 0.00% | +200.0% |
Q1 2017 | $4,360,000 | +394.9% | 123,483 | +75.6% | 0.00% | – |
Q4 2016 | $881,000 | -11.7% | 70,329 | -2.4% | 0.00% | – |
Q3 2016 | $998,000 | +62.0% | 72,022 | +15.4% | 0.00% | – |
Q2 2016 | $616,000 | -71.8% | 62,412 | -51.7% | 0.00% | – |
Q1 2016 | $2,185,000 | -32.9% | 129,212 | -11.6% | 0.00% | – |
Q4 2015 | $3,255,000 | -9.8% | 146,231 | -4.4% | 0.00% | -100.0% |
Q3 2015 | $3,608,000 | -93.7% | 152,940 | -78.1% | 0.00% | -94.1% |
Q2 2015 | $57,108,000 | +3431.7% | 698,487 | +3901.6% | 0.02% | – |
Q1 2015 | $1,617,000 | +603.0% | 17,455 | +207.5% | 0.00% | – |
Q4 2014 | $230,000 | +42.0% | 5,676 | -52.0% | 0.00% | – |
Q4 2013 | $162,000 | -48.7% | 11,819 | -29.4% | 0.00% | – |
Q3 2013 | $316,000 | – | 16,752 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
RA Capital Management | 704,701 | $24,883,000 | 3.05% |
Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
FT Options LLC | 22,834 | $806,000 | 1.06% |